Protara Therapeutics Inc
$ 4.12
0.49%
07 Aug - close price
- Market Cap 225,748,000 USD
- Current Price $ 4.12
- High / Low $ 4.17 / 4.00
- Stock P/E N/A
- Book Value 3.29
- EPS -1.40
- Next Earning Report 2026-08-10
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.24 %
- ROE -0.37 %
- 52 Week High 7.82
- 52 Week Low 2.97
About
Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, is dedicated to identifying and promoting transformative therapies for the treatment of cancer and rare diseases. The company is headquartered in New York, New York.
Analyst Target Price
$26.57
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-13 | 2026-03-10 | 2025-11-10 | 2025-08-11 | 2025-05-08 | 2025-03-05 | 2024-11-12 | 2024-08-06 | 2024-05-02 | 2024-03-13 | 2023-11-03 | 2023-08-03 |
| Reported EPS | -0.31 | -0.38 | -0.31 | -0.35 | -0.29 | -0.43 | -0.5 | -0.45 | -0.97 | -0.9 | -0.87 | -1 |
| Estimated EPS | -0.37 | -0.312 | -0.38 | -0.41 | -0.48 | -0.565 | -0.52 | -0.74 | -0.92 | -0.92 | -0.98 | -0.94 |
| Surprise | 0.06 | -0.068 | 0.07 | 0.06 | 0.19 | 0.135 | 0.02 | 0.29 | -0.05 | 0.02 | 0.11 | -0.06 |
| Surprise Percentage | 16.2162% | -21.7949% | 18.4211% | 14.6341% | 39.5833% | 23.8938% | 3.8462% | 39.1892% | -5.4348% | 2.1739% | 11.2245% | -6.383% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-10 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | -0.33 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: TARA
2026-07-31 10:10:06
This article provides a detailed financial and analytical overview of Protara Therapeutics Inc (TARA), including live stock price, market performance, and key financial figures. It highlights the company's clinical-stage biotechnology focus on cancer and rare diseases, particularly TARA-002 for bladder cancer and lymphatic malformations, and IV Choline Chloride. The analysis includes a TradingKey Stock Score, analyst ratings, technical indicators, and ownership structure.
2026-07-30 10:09:43
Protara Therapeutics Inc (TARA) has a current valuation score of 6.67, placing it 292nd out of 384 in the Biotechnology & Medical Research industry. Its P/E ratio is -2.97. However, key P/B and P/CF data have not yet been disclosed by the company.
2026-07-30 07:40:42
Protara Therapeutics Inc (TARA) has a robust financial status with a current financial score of 7.14, ranking 147 out of 384 in the Biotechnology & Medical Research industry, though its operating efficiency is low. The article provides an overview of various financial indicators, including quality of earnings, operational efficiency, growth potential, and shareholder returns, for which specific data has not yet been disclosed by the company.
2026-07-27 16:39:57
This article provides a comprehensive stock analysis of Protara Therapeutics Inc (TARA) from TradingKey, highlighting its strong fundamentals and high growth potential. The company's valuation is considered fairly valued within the Biotechnology & Medical Research industry, with high institutional ownership and multiple Buy ratings from analysts. Despite an average stock market performance recently, the stock is trading sideways, suggesting suitability for range-bound swing trading.
2026-07-27 16:39:57
Protara Therapeutics Inc (TARA) has an institutional shareholding score of 7.00, placing it 80th in the Biotechnology & Medical Research industry. The institutional shareholding proportion is 85.08%, which is a 61.63% increase quarter-over-quarter. Steven Cohen is the largest institutional shareholder, holding 1.26 million shares.
2026-07-27 07:11:20
This article from TradingKey provides a revenue breakdown for Protara Therapeutics Inc (TARA). It states that relevant data regarding business segments, regional revenue, and profit contribution for FY2019 have not been disclosed by the company yet. The article indicates a market cap of $222.36 million for TARA.
